LONDON, April 30, 2015 /PRNewswire/ --
Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of Prescient Therapeutics
Highlights of the analysis on Prescient Therapeutics by Edison's healthcare analysts Dr Dennis Hulme and Dr Mick Cooper are as follows:
Prescient acquired two promising cancer compounds that target major tumour survival pathways in 2014. The most advanced compound, PTX-200, is in Phase Ib/II trials in breast and ovarian cancers; interim data from the breast cancer study are expected in early 2016. Three additional Phase Ib/II trials are scheduled to start by June 2016, subject to funding. We value Prescient at A$35m or A$0.66 per share.
Prescient Therapeutics (previously Virax) is an ASX-listed biotechnology company focused on developing novel products for the treatment of cancer. It has two products, PTX-100 and PTX-200 in clinical development for a range of cancers. To download this report, please click here.
All reports published by Edison are available to download free of charge from its website http://www.edisongroup.com.
About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact:
Dr Dennis Hulme, Edison Investment Research, +61(0)2-9258-1161
Dr Mick Cooper, Edison Investment Research, +44(0)20-3077-5734
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
SOURCE Edison Investment Research